Endogenous regeneration: Engineering growth factors for stroke

Neurochemistry International

Volumn 107, Issue , 2017, Pages 57-65

  Chan, Su Jing ^a,b   Love, Christopher ^a,c,d   Spector, Myron ^d,e,f   Cool, Simon M ^b   Nurcombe, Victor ^b   Lo, Eng H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Agency for Science   (Singapore)

^c Massachusetts Institute of Technology   (United States)

^d VA BOSTON HEALTHCARE SYSTEM   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BRAIN DERIVED NEUROTROPHIC FACTOR; EPIDERMAL GROWTH FACTOR; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; VASCULOTROPIN; SIGNAL PEPTIDE;

BIOENGINEERING; BRAIN DAMAGE; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; CELL MIGRATION; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; HYDROGEL; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; REGENERATIVE MEDICINE; REVIEW; THERAPEUTIC INDEX; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; METABOLISM; PHYSIOLOGY; PROCEDURES; REGENERATION; TRENDS;

ANIMALS; BIOENGINEERING; DRUG DELIVERY SYSTEMS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; REGENERATION; STROKE;

EID: 85018843753     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2017.03.024     Document Type: Review

References (88)

1. Adembri, C., Massagrande, A., Tani, A., Miranda, M., Margheri, M., De Guadio, R., Pellegrini-Giampietro, D.E., Carbamylated erythropoietin is neuroprotective in an experimental model of traumatic brain injury. Crit. Care Med. 36 (2008), 975–978.
2. Alashee, A.M., Belkin, A.A., Leiderman, I.N., Ivanov, R.A., Isakova, T.M., Granulocyte-colony-stimulating factor for acute ischemic stroke: a randomized controlled trial (STEMTHER). Transl. Stroke Res. 2 (2011), 358–365.
3. Ampofo, S.A., Wang, H.M., Linhardt, R.J., Disaccharide compositional analysis of heparin and heparan sulfate using capillary zone electrophoresis. Anal. Biochem. 199 (1991), 249–255.
4. Baldauf, K., Reymann, K.G., Influence of EGF/bFGF treatment on proliferation, early neurogenesis and infarct volume after transient focal ischemia. Brain Res. 1056 (2005), 158–167.
5. Baranova, O., Miranda, L.F., Pichiule, P., Dragatsis, I., Johnson, R.S., Chavez, J.C., Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J. Neurosci. 27 (2007), 6320–6332.
6. Basu, S., Hodgson, G., Katz, M., Dunn, A.R., Evaluation of role of G-CSF in the production, survival, and release of neutrophils from bone marrow into circulation. Blood 100 (2002), 854–861.
7. Baydyuk, M., Xu, B., BDNF signaling and survival of striatal neurons. Front. Cell Neurosci., 8, 2014, 254.
8. Benders, M.J., van der Aa, N.E., Roks, M., van Straaten, H.L., Isgum, I., Viergever, M.A., Groenendaal, F., de Vries, L.S., van Bel, F., Feasibility and safety of erythropoietin for neuroprotection after perinatal arterial ischemic stroke. J. Pediatr. 164:481–486 (2014), e481–482.
9. Brines, M.L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N.C., Cerami, C., Itri, L.M., Cerami, A., Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 10526–10531.
10. Carey, D.J., Syndecans: multifunctional cell-surface co-receptors. Biochem. J. 327:Pt 1 (1997), 1–16.
11. Carpentier, P.A., Palmer, T.D., Immune influence on adult neural stem cell regulation and function. Neuron 64 (2009), 79–92.
12. Chellaiah, A., Yuan, W., Chellaiah, M., Ornitz, D.M., Mapping ligand binding domains in chimeric fibroblast growth factor receptor molecules. Multiple regions determine ligand binding specificity. J. Biol. Chem. 274 (1999), 34785–34794.
13. Chen, G., Gulbranson, D.R., Yu, P., Hou, Z., Thomson, J.A., Thermal stability of fibroblast growth factor protein is a determinant factor in regulating self-renewal, differentiation, and reprogramming in human pluripotent stem cells. Stem Cells 30 (2012), 623–630.
14. Chen, J., Zacharek, A., Li, A., Zhang, C., Ding, J., Roberts, C., Lu, M., Kapke, A., Chopp, M., Vascular endothelial growth factor mediates atorvastatin-induced mammalian achaete-scute homologue-1 gene expression and neuronal differentiation after stroke in retired breeder rats. Neuroscience 141 (2006), 737–744.
15. Cook, D.J., Nguyen, C., Chun, H.N., L Llorente, I., Chiu, A.S., Machnicki, M., Zarembinski, T.I., Carmichael, S.T., Hydrogel-delivered brain-derived neurotrophic factor promotes tissue repair and recovery after stroke. J. Cereb. Blood Flow Metab. 37 (2017), 1030–1045.
16. Cosler, L.E., Eldar-Lissai, A., Culakova, E., Kuderer, N.M., Dale, D., Crawford, J., Lyman, G.H., Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics 25 (2007), 343–351.
17. Craig, C.G., Tropepe, V., Morshead, C.M., Reynolds, B.A., Weiss, S., van der Kooy, D., In vivo growth factor expansion of endogenous subependymal neural precursor cell populations in the adult mouse brain. J. Neurosci. 16 (1996), 2649–2658.
18. DeAngelis, P.L., Liu, J., Linhardt, R.J., Chemoenzymatic synthesis of glycosaminoglycans: re-creating, re-modeling and re-designing nature's longest or most complex carbohydrate chains. Glycobiology 23 (2013), 764–777.
19. Dulaney, S.B., Huang, X., Strategies in synthesis of heparin/heparan sulfate oligosaccharides: 2000-present. Adv. Carbohydr. Chem. Biochem. 67 (2012), 95–136.
20. Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.H., Breiter, N., Jacob, S., Knerlich, F., Bohn, M., Poser, W., Ruther, E., Kochen, M., Gefeller, O., Gleiter, C., Wessel, T.C., De Ryck, M., Itri, L., Prange, H., Cerami, A., Brines, M., Siren, A.L., Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8 (2002), 495–505.
21. Ehrenreich, H., Kastner, A., Weissenborn, K., Streeter, J., Sperling, S., Wang, K.K., Worthmann, H., Hayes, R.L., von Ahsen, N., Kastrup, A., Jeromin, A., Herrmann, M., Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients. Mol. Med. 17 (2011), 1306–1310.
22. Ehrenreich, H., Weissenborn, K., Prange, H., Schneider, D., Weimar, C., Wartenberg, K., Schellinger, P.D., Bohn, M., Becker, H., Wegrzyn, M., Jahnig, P., Herrmann, M., Knauth, M., Bahr, M., Heide, W., Wagner, A., Schwab, S., Reichmann, H., Schwendemann, G., Dengler, R., Kastrup, A., Bartels, C., Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40 (2009), e647–656.
23. Ellis, F.U., Aliza, M.T., Melanie, J.B., Robert, T., Erythropoiesis-stimulating agents - time for a reevaluation. N. Engl. J. Med. 362 (2010), 189–192.
24. Encinas, M., Iglesias, M., Llecha, N., Comella, J.X., Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J. Neurochem. 73 (1999), 1409–1421.
25. Erbayraktar, S., Grasso, G., Sfacteria, A., Xie, Q.W., Coleman, T., Kreilgaard, M., Torup, L., Sager, T., Erbayraktar, Z., Gokmen, N., Yilmaz, O., Ghezzi, P., Villa, P., Fratelli, M., Casagrande, S., Leist, M., Helboe, L., Gerwien, J., Christensen, S., Geist, M.A., Pedersen, L.Ø., Cerami-Hand, C., Wuerth, J., Cerami, A., Brines, M., Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 6741–6746.
26. Falanga, A., Marchetti, M., Evangelista, V., Manarini, S., Oldani, E., Giovanelli, S., Galbusera, M., Cerletti, C., Barbui, T., Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 93 (1999), 2506–2514.
27. Fauchere, J.C., Dame, C., Vonthein, R., Koller, B., Arri, S., Wolf, M., Bucher, H.U., An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics 122 (2008), 375–382.
28. Floel, A., Warnecke, T., Duning, T., Lating, Y., Uhlenbrock, J., Scheneider, A., Vogt, G., Laage, R., Koch, W., Knecht, S., Schäbitz, W., Granulocyte-colony stimulating factor (G-CSF) in stroke patients with concomitant vascular disease—a randomized controlled trial. Plos One, 6, 2011, e19767.
29. Gautier, S., Ouk, T., Tagzirt, M., Lefebvre, C., Laprais, M., Pétrault, O., Dupont, A., Leys, D., Bordet, R., Impact of the neutrophil response to granulocyte colony-stimulating factor on the risk of hemorrhage when used in combination with tissue plasminogen activator during the acute phase of experimental stroke. J. Neuroinflammation, 11, 2014.
30. Groenen, L.C., Nice, E.C., Burgess, A.W., Structure-function relationships for the EGF/TGF-alpha family of mitogens. Growth Factor 11 (1994), 235–257.
31. Hacke, W., Albers, G., Al-Rawi, Y., Bogousslavsky, J., Davalos, A., Eliasziw, M., Fischer, M., Furlan, A., Kaste, M., Lees, K.R., Soehngen, M., Warach, S., The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36 (2005), 66–73.
32. Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Davalos, A., Guidetti, D., Larrue, V., Lees, K.R., Medeghri, Z., Machnig, T., Schneider, D., von Kummer, R., Wahlgren, N., Toni, D., Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359 (2008), 1317–1329.
33. Higginson, J.R., Thompson, S.M., Santos-Silva, A., Guimond, S.E., Turnbull, J.E., Barnett, S.C., Differential sulfation remodelling of heparan sulfate by extracellular 6-O-sulfatases regulates fibroblast growth factor-induced boundary formation by glial cells: implications for glial cell transplantation. J. Neurosci. 32 (2012), 15902–15912.
34. Hileman, R.E., Fromm, J.R., Weiler, J.M., Linhardt, R.J., Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 20 (1998), 156–167.
35. Hu, Y., Russek, S.J., BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation. J. Neurochem. 105 (2008), 1–17.
36. Ibrahimi, O.A., Zhang, F., Hrstka, S.C., Mohammadi, M., Linhardt, R.J., Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry 43 (2004), 4724–4730.
37. Jin, K., Sun, Y., Xie, L., Childs, J., Mao, X.O., Greenberg, D.A., Post-ischemic administration of heparin-binding epidermal growth factor-like growth factor (HB-EGF) reduces infarct size and modifies neurogenesis after focal cerebral ischemia in the rat. J. Cereb. Blood Flow. Metab. 24 (2004), 399–408.
38. Kiefer, B., Should we train physicians in assisted suicide?. Rev. Med. Suisse, 4, 2008, 880.
39. King, V.R., Averill, S.A., Hewazy, D., Priestley, J.V., Torup, L., Michael-Titus, A.T., Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. Eur. J. Neurosci. 26 (2007), 90–100.
40. Kreuger, J., Spillmann, D., Li, J.P., Lindahl, U., Interactions between heparan sulfate and proteins: the concept of specificity. J. Cell Biol. 174 (2006), 323–327.
41. Kuberan, B., Lech, M.Z., Beeler, D.L., Wu, Z.L., Rosenberg, R.D., Enzymatic synthesis of antithrombin III-binding heparan sulfate pentasaccharide. Nat. Biotechnol. 21 (2003), 1343–1346.
42. Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., Savino, C., Bianchi, M., Neilsen, J., Gerwien, J., Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305 (2004), 239–242.
43. Li, Q., Stephenson, D., Postischemic administration of basic fibroblast growth factor improves sensorimotor function and reduces infarct size following permanent focal cerebral ischemia in the rat. Exp. Neurol. 177 (2002), 531–537.
44. Lim, T.C., Rokkappanavar, S., Toh, W.S., Wang, L.S., Kurisawa, M., Spector, M., Chemotactic recruitment of adult neural progenitor cells into multifunctional hydrogels providing sustained SDF-1alpha release and compatible structural support. FASEB J. 27 (2013), 1023–1033.
45. Lim, T.C., Toh, W.S., Wang, L.S., Kurisawa, M., Spector, M., The effect of injectable gelatin-hydroxyphenylpropionic acid hydrogel matrices on the proliferation, migration, differentiation and oxidative stress resistance of adult neural stem cells. Biomaterials 33 (2012), 3446–3455.
46. Lindahl, U., Kusche-Gullberg, M., Kjellen, L., Regulated diversity of heparan sulfate. J. Biol. Chem. 273 (1998), 24979–24982.
47. Liu, R., Xu, Y., Chen, M., Weiwer, M., Zhou, X., Bridges, A.S., DeAngelis, P.L., Zhang, Q., Linhardt, R.J., Liu, J., Chemoenzymatic design of heparan sulfate oligosaccharides. J. Biol. Chem. 285 (2010), 34240–34249.
48. Matsuo, R., Ago, T., Kamouchi, M., Kuroda, J., Kuwashiro, T., Hata, J., Sugimori, H., Fukuda, K., Gotoh, S., Makihara, N., Fukuhara, M., Awano, H., Isomura, T., Suzuki, K., Yasaka, M., Okada, Y., Kiyohara, Y., Kitazono, T., Clinical significance of plasma VEGF value in ischemic stroke - research for biomarkers in ischemic stroke (REBIOS) study. BMC Neurol., 13, 2013, 32.
49. Minnerup, J., Heidrich, J., Wellmann, J., Rogalewski, A., Schneider, A., Schabitz, W.R., Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia. Stroke 39 (2008), 1855–1861.
50. Murali, S., Rai, B., Dombrowski, C., Lee, J.L., Lim, Z.X., Bramono, D.S., Ling, L., Bell, T., Hinkley, S., Nathan, S.S., Hui, J.H., Wong, H.K., Nurcombe, V., Cool, S.M., Affinity-selected heparan sulfate for bone repair. Biomaterials 34 (2013), 5594–5605.
51. Nih, L.R., Carmichael, S.T., Segura, T., Hydrogels for brain repair after stroke: an emerging treatment option. Curr. Opin. Biotechnol. 40 (2016), 155–163.
52. Orefice, L.L., Waterhouse, E.G., Partridge, J.G., Lalchandani, R.R., Vicini, S., Xu, B., Distinct roles for somatically and dendritically synthesized brain-derived neurotrophic factor in morphogenesis of dendritic spines. J. Neurosci. 33 (2013), 11618–11632.
53. Ori, A., Wilkinson, M.C., Fernig, D.G., The heparanome and regulation of cell function: structures, functions and challenges. Front. Biosci. 13 (2008), 4309–4338.
54. Perrimon, N., Bernfield, M., Specificities of heparan sulphate proteoglycans in developmental processes. Nature 404 (2000), 725–728.
55. Price, C.D., Yang, Z., Karlnoski, R., Kumar, D., Chaparro, R., Camporesi, E.M., Effect of continuous infusion of asialoerythropoietin on short-term changes in infarct volume, penumbra apoptosis and behaviour following middle cerebral artery occlusion in rats. Clin. Exp. Pharmacol. Physiol. 37 (2010), 185–192.
56. Prydz, K., Dalen, K.T., Synthesis and sorting of proteoglycans. J. Cell Sci. 113:Pt 2 (2000), 193–205.
57. Pye, D.A., Vives, R.R., Turnbull, J.E., Hyde, P., Gallagher, J.T., Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J. Biol. Chem. 273 (1998), 22936–22942.
58. Rai, B., Chatterjea, A., Lim, Z.X., Tan, T.C., Sawyer, A.A., Hosaka, Y.Z., Murali, S., Lee, J.J., Fenwick, S.A., Hui, J.H., Nurcombe, V., Cool, S.M., Repair of segmental ulna defects using a beta-TCP implant in combination with a heparan sulfate glycosaminoglycan variant. Acta Biomater. 28 (2015), 193–204.
59. Rapraeger, A.C., Krufka, A., Olwin, B.B., Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252 (1991), 1705–1708.
60. Ren, J.M., Finklestein, S.P., Growth factor treatment of stroke. Curr. Drug Targets CNS Neurol. Disord. 4 (2005), 121–125.
61. Ringelstein, E.B., Thijs, V., Norrving, B., Chamorro, A., Aichner, F., Grond, M., Saver, J., Laage, R., Schneider, A., Rathgeb, F., Vogt, G., Charisse, G., Fiebach, J.B., Schwab, S., Schabitz, W.R., Kollmar, R., Fisher, M., Brozman, M., Skoloudik, D., Gruber, F., Serena Leal, J., Veltkamp, R., Kohrmann, M., Berrouschot, J., Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke 44 (2013), 2681–2687.
62. Sarrazin, S., Lamanna, W.C., Esko, J.D., Heparan sulfate proteoglycans. Cold Spring Harb. Perspect. Biol., 3, 2011.
63. Sato, T., Maekawa, T., Watanabe, S., Tsuji, K., Nakahata, T., Erythroid progenitors differentiate and mature in response to endogenous erythropoietin. J. Clin. Invest 106 (2000), 263–270.
64. Schabitz, W.R., Berger, C., Kollmar, R., Seitz, M., Tanay, E., Kiessling, M., Schwab, S., Sommer, C., Effect of brain-derived neurotrophic factor treatment and forced arm use on functional motor recovery after small cortical ischemia. Stroke 35 (2004), 992–997.
65. Schabitz, W.R., Kollmar, R., Schwaninger, M., Juettler, E., Bardutzky, J., Scholzke, M.N., Sommer, C., Schwab, S., Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke 34 (2003), 745–751.
66. Schabitz, W.R., Laage, R., Vogt, G., Koch, W., Kollmar, R., Schwab, S., Schneider, D., Hamann, G.F., Rosenkranz, M., Veltkamp, R., Fiebach, J.B., Hacke, W., Grotta, J.C., Fisher, M., Schneider, A., AXIS: a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke. Stroke 41 (2010), 2545–2551.
67. Schneider, A., Kruger, C., Steigleder, T., Weber, D., Pitzer, C., Laage, R., Aronowski, J., Maurer, M.H., Gassler, N., Mier, W., Hasselblatt, M., Kollmar, R., Schwab, S., Sommer, C., Bach, A., Kuhn, H.G., Schabitz, W.R., The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J. Clin. Invest 115 (2005), 2083–2098.
68. Semenza, G.L., Wang, G.L., A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell Biol. 12 (1992), 5447–5454.
69. Siren, A.L., Knerlich, F., Poser, W., Gleiter, C.H., Bruck, W., Ehrenreich, H., Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol. 101 (2001), 271–276.
70. Souvenir, R., Flores, J.J., Ostrowski, R.P., Manaenko, A., Duris, K., Tang, J., Erythropoietin inhibits HIF-1alpha expression via upregulation of PHD-2 transcription and translation in an in vitro model of hypoxia-ischemia. Transl. Stroke Res. 5 (2014), 118–127.
71. Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X.O., Logvinova, A., Greenberg, D.A., VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Invest 111 (2003), 1843–1851.
72. Taipale, J., Keski-Oja, J., Growth factors in the extracellular matrix. FASEB J. 11 (1997), 51–59.
73. Tureyen, K., Vemuganti, R., Bowen, K.K., Sailor, K.A., Dempsey, R.J., EGF and FGF-2 infusion increases post-ischemic neural progenitor cell proliferation in the adult rat brain. Neurosurgery 57 (2005), 1254–1263.
74. Turnbull, J.E., Gallagher, J.T., Heparan sulphate: functional role as a modulator of fibroblast growth factor activity. Biochem. Soc. Trans. 21 (1993), 477–482.
75. Tyler, P.C., Guimond, S.E., Turnbull, J.E., Zubkova, O.V., Single-entity heparan sulfate glycomimetic clusters for therapeutic applications. Angew. Chem. Int. Ed. Engl. 54 (2015), 2718–2723.
76. Uniewicz, K.A., Ori, A., Xu, R., Ahmed, Y., Wilkinson, M.C., Fernig, D.G., Yates, E.A., Differential scanning fluorimetry measurement of protein stability changes upon binding to glycosaminoglycans: a screening test for binding specificity. Anal. Chem. 82 (2010), 3796–3802.
77. Vlodavsky, I., Fuks, Z., Ishai-Michaeli, R., Bashkin, P., Levi, E., Korner, G., Bar-Shavit, R., Klagsbrun, M., Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis. J. Cell Biochem. 45 (1991), 167–176.
78. Wada, K., Sugimori, H., Bhide, P.G., Moskowitz, M.A., Finklestein, S.P., Effect of basic fibroblast growth factor treatment on brain progenitor cells after permanent focal ischemia in rats. Stroke 34 (2003), 2722–2728.
79. Wang, C., Poon, S., Murali, S., Koo, C.Y., Bell, T.J., Hinkley, S.F., Yeong, H., Bhakoo, K., Nurcombe, V., Cool, S.M., Engineering a vascular endothelial growth factor 165-binding heparan sulfate for vascular therapy. Biomaterials 35 (2014), 6776–6786.
80. Wang, L., Zhang, Z., Wang, Y., Zhang, R., Chopp, M., Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 35 (2004), 1732–1737.
81. Wang, Y., Cooke, M.J., Sachewsky, N., Morshead, C.M., Shoichet, M.S., Bioengineered sequential growth factor delivery stimulates brain tissue regeneration after stroke. J. Control Release 172 (2013), 1–11.
82. Worthmann, H., Martens-Lobenhoffer, J., Joumaah, M., Li, N., Lichtinghagen, R., Hecker, H., Kielstein, J.T., Ehrenreich, H., Bode-Boger, S.M., Weissenborn, K., Asymmetric dimethylarginine in response to recombinant tissue-type plasminogen activator and erythropoietin in acute stroke. Stroke 44 (2013), 2128–2133.
83. Xing, C., Hayakawa, K., Lo, E.H., Mechanisms, imaging, and therapy in stroke recovery. Transl. Stroke Res. 8 (2016), 1–2.
84. Xu, D., Esko, J.D., Demystifying heparan sulfate-protein interactions. Annu. Rev. Biochem. 83 (2014), 129–157.
85. Yamashita, K., Wiessner, C., Lindholm, D., Thoenen, H., Hossmann, K.A., Post-occlusion treatment with BDNF reduces infarct size in a model of permanent occlusion of the middle cerebral artery in rat. Metab. Brain Dis. 12 (1997), 271–280.
86. Yarbrough, C.K., Ong, C.J., Beyer, A.B., Lipsey, K., Derdeyn, C.P., Endovascular thrombectomy for anterior circulation stroke: systematic review and meta-analysis. Stroke 46 (2015), 3177–3183.
87. Zechariah, A., Elali, A., Hermann, D.M., Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice. Stroke 41 (2010), 1008–1012.
88. Zhang, Z.G., Zhang, L., Jiang, Q., Zhang, R., Davies, K., Powers, C., Bruggen, N., Chopp, M., VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J. Clin. Invest 106 (2000), 829–838.